A San Diego-based dermatological company has reached the completion date for its trial into the safety and efficacy of a product used on men with hereditary hair loss.
While no official announcement about the completion of the trial has yet been made, it is believed that Intrepid Therapeutics’ investigation into using a solution known as CB-03-01 on people with male pattern baldness finished in April. The study was first registered back in October 2014.
Compared to Minoxidil
The company had been comparing a 5 per cent solution of a drug named CB-03-01, also known as Cortexolone 17α-Propionate, to the well-known hair loss drug Minoxidil in the trial, which also saw some participants given a placebo.
The researchers’ aims were to measure changes in the target area hair count, changes from baseline in the target area hair count, and also to see what test subjects thought of the treatment, with participants asked to rate their growth on a scale from -3 (greatly decreased hair growth) to +3 (greatly increased).
There is currently no information available about the team’s findings, however as soon as their results are published we will post them here on the Belgravia blog.
The trial information at clinicaltrials.gov gives little away about CB-03-01, though it appears that a 1 per cent strength version of the drug has previously been trialled as a possible treatment for acne vulgaris. According to various internet reports, the drug “tightly mimics the profile of an ideal anti-androgen for topical use.”
It also appears that CB-03-01 is actually a molecule patented by an Italian pharmaceutical company named Cosmo, whose website confirms that it is “a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.”
Topical use means that the drug is applied directly to the skin, rather than being taken in pill form. When this option is available, many people prefer this route as they feel they are getting their medication to the exact spot it is needed. Side-effects associated with orally-taken drugs can sometimes be avoided with topical treatments, too.
Clinically-proven and MHRA-approved, Minoxidil is also applied topically and has proven extremely popular since its discovery, not least because it has been seen to produce such encouraging regrowth results for both men and women. At Belgravia we often recommend high strength minoxidil formulations for treating stubborn areas of hair loss, such as a receding hairline, and this can be used alongside boosters for a fully proactive approach.
Furthermore, when men couple minoxidil with a product named Finasteride 1mg – which is taken once daily in pill form and should not be used topically – the cause of Male Pattern Baldness, the hormone byproduct DHT, can be inhibited thereby stabilising shedding and further encouraging new hair growth.
An experienced specialist can advise on how these products work and which preparations and combinations best suit each individual as part of a personalised hair loss treatment course.
The Belgravia Centre
The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.